<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503229</url>
  </required_header>
  <id_info>
    <org_study_id>7639</org_study_id>
    <secondary_id>NCI-2011-03745</secondary_id>
    <secondary_id>0801</secondary_id>
    <secondary_id>7639</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01503229</nct_id>
    <nct_alias>NCT01508234</nct_alias>
  </id_info>
  <brief_title>Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer</brief_title>
  <official_title>Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well abiraterone acetate works in treating patients with&#xD;
      hormone-resistant prostate cancer that has spread from the primary site (place where it&#xD;
      started) to other places in the body (metastatic). Abiraterone acetate may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the magnitude of tissue testosterone suppression by abiraterone acetate in&#xD;
      metastatic castrate-resistant prostate cancer (CRPC) (resistant to luteinizing&#xD;
      hormone-releasing hormone [LHRH] agonist or orchiectomy Â± antiandrogen) after one month of&#xD;
      treatment to establish tissue based mechanism of action.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive abiraterone acetate orally once daily and prednisone twice daily on days&#xD;
      1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tissue Testosterone and Dihydrotestosterone</measure>
    <time_frame>From baseline to week 4</time_frame>
    <description>Tissue testosterone will be measured in biopsy tissues</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hormone-Resistant Prostate Cancer</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (abiraterone acetate and prednisone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive abiraterone acetate orally once daily and prednisone orally twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Treatment (abiraterone acetate and prednisone)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (abiraterone acetate and prednisone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (abiraterone acetate and prednisone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (abiraterone acetate and prednisone)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have signed an informed consent document indicating that the subjects understands the&#xD;
             purpose of and procedures required for the study and are willing to participate in the&#xD;
             study&#xD;
&#xD;
          -  Written authorization for use and release of health and research study information has&#xD;
             been obtained&#xD;
&#xD;
          -  Be willing/able to adhere to the prohibitions and restrictions specified in this&#xD;
             protocol&#xD;
&#xD;
          -  Able to swallow the study drug whole as a tablet&#xD;
&#xD;
          -  Willing to take abiraterone acetate on an empty stomach; no food should be consumed at&#xD;
             least two hours before and for at least one hour after the dose of abiraterone acetate&#xD;
             is taken&#xD;
&#xD;
          -  Patients who have partners of childbearing potential must be willing to use a method&#xD;
             of birth control with adequate barrier protection as determined to be acceptable by&#xD;
             the principal investigator and sponsor during the study and for 1 week after last dose&#xD;
             of abiraterone acetate&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the prostate&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Metastatic castration resistant prostate cancer as defined by serum testosterone &lt; 50&#xD;
             ng/ml and one of the following:&#xD;
&#xD;
               -  Prostate specific antigen (PSA) level of at least 2 ng/ml that has risen on at&#xD;
                  least 2 successive occasions at least 1 week apart&#xD;
&#xD;
               -  Evaluable disease progression by modified RECIST (Response Evaluation Criteria in&#xD;
                  Solid Tumors)&#xD;
&#xD;
               -  Progression of metastatic bone disease on bone scan with &gt; 2 new lesions&#xD;
&#xD;
          -  Maintenance of Lupron or antagonist unless previously treated with orchiectomy&#xD;
&#xD;
          -  The presence of metastatic disease amenable to computed tomography (CT) or ultrasound&#xD;
             guided biopsy; this may include thoracolumbar vertebral bodies, pelvis, femur or&#xD;
             humerus, or soft tissue or nodal metastasis amenable to biopsy (excluding lung or&#xD;
             pleural lesions)&#xD;
&#xD;
          -  Patients may have received secondary hormonal manipulations (excluding prior&#xD;
             abiraterone acetate, MDV3100 or TAK700) or up to two lines of chemotherapy; all prior&#xD;
             therapy except Lupron must have been discontinued for more than 4 weeks before&#xD;
             enrollment&#xD;
&#xD;
          -  Serum potassium of &gt;= 3.5 mEq/L&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &lt; 1.5 x upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Bilirubin levels &lt; 1.5 x ULN&#xD;
&#xD;
          -  Serum albumin of &gt;= 3.0 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  Platelet count of &gt;= 100,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count of &gt; 1,500 cell/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection or other medical condition that would make prednisone/prednisolone&#xD;
             (corticosteroid) use contraindicated&#xD;
&#xD;
          -  Patients who are currently receiving active therapy for other neoplastic disorders&#xD;
             will not be eligible&#xD;
&#xD;
          -  Patients with histologic evidence of small cell carcinoma of the prostate will not be&#xD;
             eligible&#xD;
&#xD;
          -  Known brain metastasis&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure [BP] &gt;= 160 mmHg or diastolic BP &gt;=&#xD;
             95 mmHg); patients with a history of hypertension are allowed provided blood pressure&#xD;
             is controlled by anti-hypertensive treatment&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
          -  History of pituitary or adrenal dysfunction&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt; 50 % at baseline&#xD;
&#xD;
          -  Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy&#xD;
&#xD;
          -  Administration of an investigational therapeutic within 30 days of screening&#xD;
&#xD;
          -  Patients with dementia/psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements or would prohibit the understanding and/or giving&#xD;
             of informed consent will not be eligible&#xD;
&#xD;
          -  Patients with any condition that, in the opinion of the investigator, would compromise&#xD;
             the well-being of the subject or the study or prevent the subject from meeting or&#xD;
             performing study requirements&#xD;
&#xD;
          -  Patients requiring therapeutic anticoagulation (e.g., warfarin, dabigatran, heparin,&#xD;
             or low molecular weight heparins [Lovenox, dalteparin])&#xD;
&#xD;
          -  Patients with poorly controlled diabetes&#xD;
&#xD;
          -  Patients with a history of gastrointestinal disorders (medical disorders or extensive&#xD;
             surgery) that may interfere with the absorption of the study agents&#xD;
&#xD;
          -  Patients with a pre-existing condition that warrants long-term corticosteroid use in&#xD;
             excess of study dose&#xD;
&#xD;
          -  Patients with known allergies, hypersensitivity, or intolerance to abiraterone acetate&#xD;
             or prednisone or their excipients&#xD;
&#xD;
          -  Child-Pugh class B or C hepatic impairment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Montgomery</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 27, 2011</study_first_submitted>
  <study_first_submitted_qc>December 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <results_first_submitted>March 8, 2021</results_first_submitted>
  <results_first_submitted_qc>April 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2021</results_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Bruce Montgomery</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01503229/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Abiraterone Acetate and Prednisone)</title>
          <description>Patients receive abiraterone acetate daily and prednisone twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given orally&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies&#xD;
Prednisone: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Abiraterone Acetate and Prednisone)</title>
          <description>Patients receive abiraterone acetate daily and prednisone twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given orally&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies&#xD;
Prednisone: Given orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age of participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="44" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Tissue Testosterone and Dihydrotestosterone</title>
        <description>Tissue testosterone will be measured in biopsy tissues</description>
        <time_frame>From baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Abiraterone Acetate and Prednisone)</title>
            <description>Patients receive abiraterone acetate daily and prednisone twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given orally&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies&#xD;
Prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Testosterone and Dihydrotestosterone</title>
          <description>Tissue testosterone will be measured in biopsy tissues</description>
          <units>pg/mg</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" lower_limit="0.019" upper_limit="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events only were collected over the duration of the study from enrollment through disenrollment for the last patient. Total maximum time on study was 2 years.</time_frame>
      <desc>No adverse events beyond SAE were collected given that the medication was standard of care. SAE were tracked related to any morbidity related to biopsy</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Abiraterone Acetate and Prednisone)</title>
          <description>Patients receive abiraterone acetate orally once daily and prednisone orally twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Abiraterone Acetate: Given by mouth&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Pharmacological Study: Correlative studies&#xD;
Prednisone: Given by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bruce Montgomery</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-598-0860</phone>
      <email>rbmontgo@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

